Dr Alan Fraser

Associate Professor (MB, ChB, MD, FRACP)

Gastroenterologist and Hepatologist

Dr Alan Fraser is available for consultation at

Mercy Specialist Centre,
100 Mountain Rd,
Epsom,
Auckland,
New Zealand.

Ph. 64 9 630 1838
Fx. 64 9 630 8589

---

Background

• He completed a research degree at the Royal Free Hospital, London on Helicobacter pylori infection, gastric acid secretion and protection of the gastric mucosa.
• He has been back to England for another year of research - this time in Oxford - studying Inflammatory bowel disease.
• He has written over a 130 research papers.  His current interests are primarily in the interaction between diet and genetics in Crohn's disease.
• He has an active role in teaching gastroenterology and medicine at the University of Auckland Medical School.

     

Dr Alan Fraser

 

Qualifications

MB ChB 1980 (Otago), FRACP 1990, MD (Otago)1994

Profile

I am available for consultation in all areas of gastrointestinal and liver disease and have extensive experience in diagnostic and therapeutic gastroscopy and colonoscopy.

I have been involved in research into gastrointestinal disease since 1985.  I have published over 120 original articles and many reviews.  My research interests include Helicobacter pylori infection, control of gastric acidity and gastro-oesophageal reflux, inflammatory bowel disease and gastrointestinal pharmacology.

Post Fellowship Training:

Research Fellow Royal, Free Hospital, London (1990-92)

Honorary Consultant, John Radcliffe Hospital, Oxford and Research Fellow, University of Oxford (1999-2000)

Current Appointments:

Associate Professor of Medicine, Department of Medicine, University of Auckland (since 1992).

Gastroenterologist, Auckland Gastroenterology, Mercy Specialist Centre

Member, Editorial Board, Alimentary Pharmacology and Therapeutics (since 1995)

Past president, New Zealand Society of Gastroenterology and Executive member (2002-2015)

Past chair of the SAC (specialist training subcommittee of RACP) for Gastroenerology (2004-2012)

Member of PTAC (Pharmacology and Therapeutics Advisory Committee) and Gastro-intestinal subcommittee of PTAC

Past chair of Specialist group, Mercy Ascot Endoscopy

 

Website

www.aucklandgastro.co.nz

I have written a comprehensive patient information website giving easily readable information on all gut and liver conditions and symptoms. 

www.gastro-info.co.nz

PUBLISHED ARTICLES:

 

1.          Fraser AG, Henley JW, Ellis-Pegler RB, Benjamin CS, Childs WJ, Harvey VJ. The acquired immunodeficiency syndrome in Auckland in 1985.  New Zealand Medical Journal 1986:99; 485-488

 

2.          Fraser AG, Croxson MS, Ellis-Pegler RB.  Hypercalcaemia and elevated 1,25 dihydroxy-vitamin D3 levels in a patient with multibacillary leprosy and type 1 leprosy reaction.  New Zealand Medical Journal. 1987:100; 86.

 

3.          Fraser AG, Croxson MS, Espiner EA, Synek B.  Adrenocortical carcinoma presenting as primary aldosteronism in a young man.  Australian New Zealand Journal of Medicine 1987:17; 60-62.

 

4.          Ellis-Pegler RB, Beeching NJ, Eales M, Fraser AG, Wells AU.  Fansimef is effective treatment for imported malaria in New Zealand. Australian New Zealand Journal of Medicine 1988:18; 733-734.

 

5.          Browett PJ, Fraser AG, Varcoe AR, Ellis-Pegler RB.  Disseminated tuberculosis complicated by hemophagocytic syndrome.  Australian New Zealand Journal of Medicine 1988:18; 79-80.

6.          Fraser AG. Medicine in rural Kenya - a personal perspective.  New Zealand Medical Journal 1989:102; 15-16.

 

7.          Ellis-Pegler RB, Fraser AG, Wells AU. Fansimef in the treatment of malaria. Australian New Zealand J of Medicine 1989; 19: 411.

 

8.          Fraser AG, Hamilton I. Endoscopic palliation of malignant obstructive jaundice.  New Zealand Medical Journal 1989:102; 155-157.

 

9.          Fraser AG,  Parr DH,  Ellis-Pegler RB. The spectrum of systemic candidiasis at Auckland Hospital.  New Zealand Medical Journal 1990:103; 505-507.

 

10.       Fraser AG, Arthur J, Hamilton I.  Intestinal psuedo-obstruction secondary to gastrointestinal amyloidosis responsive to treatment with cisapride.  Digestive Diseases and Sciences 1991:36; 532-535.

 

11.       Fraser AG, Prewett EJ, Sawyer AM, Rosalki SB, Pounder RE. The effect of ranitidine, cimetidine of famotidine on low-dose post-prandial alcohol absorption.  Alimentary Pharmacology and Therapeutics 1991;5:263-272.

 

12.       Fraser AG, Luk YW, Savage K, Debnam ES, Dhillon AP, Pounder RE.  Gastric mucosal proliferative response to anti-secretory drugs: labelling index and S-phase duration assessed by double-labelling.  Eur J Gastroenterol Hepatol 1991; 3 (suppl 1) A149.

 

13.       Fraser AG, Pounder RE.  H2-antagonists and alcohol. Reply. Aliment Pharmacol Therapeutics 1991;5: 668-670.

 

14.       Prewett EJ, Nwokolo CU, Hudson M, Sawyerr AM, Fraser AG, Pounder RE. The effect of GR 122311X, a bismuth compound with H2-antagonist activity, on 24-hour acidity. Alimentary Pharmacology Therapeutics 1991;5: 481-490.

 

15.       Charkravanty BK, Fraser AG, Hamilton I, Lane M.  A randomised, blinded study in colonic lavage for colonoscopy. Australian and New Zealand Journal of Medicine 1991;21: 769-771.

 

16.       Fraser AG, Debnam ES, Dhillon AP, Pounder RE.  Gastric epithelial cell proliferation after dosing with anti-secretory drugs: the effect of variation in the strain of rat.  European Journal of Gastroenterolgy and Hepatology 1992; 4:651-656 

 

17.       Fraser AG, Nicholson GI.  Duodenal perforation in primary systemic amyloidosis. Gut 1992; 33: 997-9.

 

18.       Fraser AG, Prewett EJ, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE. Ranitidine has no effect on post-prandial absorption of alcohol (0.6g/kg) after an evening meal.  European Journal Gastroenterology and Hepatology 1992;4: 43-48.

 

19.       Fraser AG, Debnam ES, Dhillon AP, Pounder RE. Gastric epithelial cell proliferation and histological damage after dosing with hypertonic saline: the effect of variation in the strain of rat. International Journal Experimental Pathology 1992; 73: 241-250

 

20.       Fraser AG, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE. The effect of ranitidine on the post-prandial absorption of a low dose of alcohol. Alimentary Pharmacology Therapeutics 1992; 6: 267-271

21.       Fraser AG, Pounder RE.  H2-antagonists and alcohol. Reply. Aliment Pharmacol Therapeutics 1991;5: 668-670.

 

22.       Fraser AG, Prewett EJ, Pounder RE, Samloff IM. Twenty-four hour hyperpepsinogenaemia in Helicobacter pylori-positive subjects is abolished by eradication of the infection. Alimentary Pharmacology Therapeutics 1992, 6:483-394

 

23.       Pounder RE, Fraser AG.  Safety concerns related to the treatment of peptic ulceration. Current opinion in Gastroenterology 1992;7: 894-899.

 

24.       Prewett EJ, Luk YW, Fraser AG, Lam WM, Pounder RE.  Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test. Alimentary Pharmacology and Therapeutics 1992;6: 97-102.

 

25.       Fraser AG, Hudson M, Sawyer AM, Smith M, Rosalki SB, Pounder RE. Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal.  Alimentary Pharmacology and Therapeutics 1992;6: 693-700

 

26.       Fraser AG, Nicholson GI.  Long-term follow-up of dilatation treatment of oesophageal strictures. J Gastroenterology and Hepatology 1992, 7: 520-523

 

27.       Fraser AG, White C, Nicholson G.  Antral vascular ectasia.  N.Z.Med J  1992; 105: 338-9.

28.       Fraser AG, Bickley J, Owen R, Pounder RE.  DNA fingerprints of Helicobacter pylori before and after treatment with omeprazole.  J Clinical Pathology 1992; 45: 1062-1065.

29.       Fraser AG, Bickley J, Owen  RJ, Pounder RE.  Genomic heterogeneity in Helicobacter pylori: achlorhydria at time of colonisation unlikely to be a factor.  Gastroenterology 1992; 102: A70.

30.       Fraser AG, Lam WM, Luk YW, Sawyerr AM, Hudson M, Smith M, Pounder RE.  The effect of ranitidine bismuth citrate on post-prandial plasma gastrin and plasma pepsinogens. Gut 1993;34: 338-342

31.       Fraser AG, Sawyerr AM, Hudson M, Smith M, Pounder RE. The effect of ranitidine on post-breakfast alcohol absorption. American Journal of Gastroenterology 1993;88: 217-221

32.       Fraser AG, Pounder RE, Burroughs AK. Gastric secretion and peptic ulcer in cirrhosis.  Journal of Hepatology 1993; 19: 171-182

 

33.       Wyeth JW, Eng K, Fraser AG, Sankey EA, Dhillon AP, Pounder RE.  Gastric mucosal CD3/CD4 lymphocytes and antigen presenting cells before and after triple therapy for Helicobacter pylori infection.  Gastroenterology 1993; 104: A804.

 

34.       Bickley J, Owen RJ, Fraser AG, Pounder RE.  Evaluation of the polymerase chain reaction for detecting the urease gene of Helicobacter pylori in gastric biopsies and dental plaque.  Journal of Medical Microbiology 1993; 39: 338-344.

 

35.       Fraser AG, Owen RJ, Bickley J, Hurtado A, Pounder, RE. Use of rRNA gene profiling and polymerase chain reaction-based restriction length polymorphism analysis of urease genes to monitor Helicobacter pylori infected patients on triple therapy. Journal of Clinical Microbiology 1994 32, 1203-1210.

 

36.       Davis JP, Wyeth JW, Fraser AG, Sercombe JC, Radcliffe GJ, Pounder RE.  Gastroesophageal reflux in patients with throat symptoms: a double-blind trial of ranitidine therapy.  Clin Otol 1994; 19: A364.

 

37.       Fraser AG, Sawyerr AM, Hudson M, Smith M, Pounder RE.  Effects of ranitidine 150 mg qds on 24-hour intragastric acidity and 24-h plasma gastrin concentration.  Digestive Diseases and Sciences 1994; 39: 91-96.

 

38.       Owen RJ, Bickley J, Hurtado A, Fraser AG and Pounder RE.  Use of rRNA gene profiling and polymerase chain reaction-based restriction length polymorphism analysis of urease genes to monitor Helicobacter pylori infecting patients on triple therapy.  Journal of Clinical Microbiology; 1994; 32: 1203-1210.

 

39.       Fraser AG, Sim R, Sankey EA, Dhillon AP, Pounder RE.  Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation. Aliment Pharmacol Therap 1994; 8: 167-173.

 

40.       Fraser AG, Haystead A, Ali MR, Tebbut S, Rose T.  Can a simplified C13 urea breath test be used as a screening test prior to endoscopy.  J Gastroenterol Hepatol 1994; 9: A88.

 

41.       Fraser AG, Lewin JF, Pounder RE.  Gastric persorption of bismuth from ranitidine bismuth citrate.  Aliment Pharmacol Therap 1995:9:447-450.

 

42.       Holford NHG, Fraser A. Population pharmacokinetics of ethanol in humans – influence of dose, meals, H2-antagonists, race and ethanol use. Clin Pharmaocology & Therapeutics 1995; 57:216.

 

43.       Fraser AG, Berry S, Moore L, Chua L, Peng S, Arroll B, Lloyd T. How many patients would benefit from eradication treatment - a general practice review.  Journal of Gastroenterol Hepatol 1995; 10(suppl2): 41-41.

 

44.       Fraser AG, Rosalki SB, Gamble GG, Pounder RE.  Inter-individual and intra-individual variabililty of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal.  Br J Clin Pharmacol 1995;40:387-392.

 

45.       Fraser AG.   Specificity of Helicobacter pylori serology.   NZ Med J 1996; 109: 304.

 

46.       Fraser AG, Ali MR, McCullough S, Haystead A.  Diagnostic tests for Helicobacter pylori - can they help select patients for endoscopy?  NZ Med J 1996; 109: 95-8.

47.       Fraser AG, Moore L, Ali MR, Hollis B, Little SV.  An audit of low dose triple therapy for eradication of Helicobacter pylori.  NZ Med J 1996; 109; 290-2

48.       Fraser AG, Sawyerr AM,  Hudson M, Smith MS, Pounder RE.  Morning versus evening dosing of lansoprazole 30mg daily on 24‑hour intragastric acidity in healthy subjects. Aliment Pharmacol Therap 1996; 10: 523-527.

49.       Scragg RK, Fraser A, Metcalf PA.  Helicobacter pylori and cardiovascular risk factors in a multicultural workforce.  J Epid Comm Health 1996:50:578-79.

50.       O’Morian C, Dettmer A, Rambow A, von Fritsch E, Fraser AG.   Double-blind multinational, multicentre, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori associated duodenal ulcer.  Helicobacter 1996; 1:130-137.

51.       Fraser AG, Scragg R, Metcalf P, McCullough S, Yeates NJ.  Prevalence of Helicobacter pylori in different ethnic groups in New Zealand children and adults. Aust NZ J Med 1996; 26:646-51 (with editorial).
 

52.       Fraser AG, Moore L, Berry S,  Arroll B.  Eradication treatment for Helicobacter pylori in general practice.  NZ Med J 1996; 109:422-4.

53.       Berry S, Arroll B, Fraser AG, Weller D. Screening for colorectal cancer:  a survey of New Zealand general practitioners.  NZ Med J 1996; 109:447-9.

54.       Perez-Perez GI, Bhat N, Gaensbauer J, Fraser AG, Taylor DN, Kuipers EJ, Zhang L, You WC, Blaser MJ.  Country-specific constancy by age in CagA+ proportion of Helicobacter pylori infections.  Int J of Cancer 1997; 72: 453-56.

55.       Fraser AG, Schreuder V, Chua LE, Moore L. Symptom profile and H-pylori recrudescence after successful eradication treatment - 1 year follow-up. Gut 1997;41:A72.

56.       Schmid J, Fraser AG, Hollis B, O’Toole P.  Ethnic tropism of DNA fingerprints of Helicobacter pylori.  Infection and Immunity 1997; 65: 3708-12.

57.       Perssons ST, Christie M, Allen J, Fraser A, Gane EJ.  A review of MALT lymphoma in New Zealand. J Gastroenterol Hepatol 1997;

58.       Fraser, A. G., McIntosh, C., Berry, S., & Moore, L. (1997). The urea breath test (UBT) for H-pylori in the initial assessment of dyspepsia in primary care. Gut 1997; 41: A77-A78.

 

59.       Fraser AG, Peng S-L, Jass JR.  Intestinal metaplasia subtypes and Helicobacter pylori infection - a comparison of ethnic groups in New Zealand. 
J Gastro Hepatol 1998; 13: 560-565.

60.       Fraser AG,  McIntosh C, Berry S, Moore L.  Can the urea breath test for H.pylori replace endoscopy for the assessment of dyspepsia in primary care?  N Z J Med 1998; 111; 11-4.

61.       Fraser AG, Schreuder V, Chua L, Moore L.  Follow-up after successful eradication of H.pylori - symptoms and re-infection.  J Gastro Hepatol 1998; 13: 555-59.

62.       Perssons S, Lane MR, Fraser AG.  Long-term follow-up of the management of oesophageal strictures at Auckland Hospital 1990-94.  NZ Med J 1999; 112: 28-29.

63.       Garrigan K, McIntosh C, Fraser AG.  Bleeding peptic ulcers: audit of eradication for H.pylori.  NZ Med J 1999; 112: 178-180.

64.       Fraser AG, Woollard GA.  Gastric juice ascorbic acid is related to Helicobacter pylori infection bit not ethnicity.  J Gastro Hepatol 1999; 14: 1070-73.

65.       Fraser AG, Moore L, Hackett M, Hollis B.  H.pylori treatment and antibiotic susceptibility: results of a five-year audit.   Aust NZ J Med 1999; 29:512-517.

66.       Fraser AG, Morton RP, Gillebrand J.  Presumed laryngo-pharyngeal reflux; investigate or treat.  J Otolaryngology 2000; 114: 441-47.

67.       Watanabe K, Simmon JD, Orchard TR, Fraser AG, Marshall SE, Welsh KI, Jewell DP.  Allelic variants of thiopurine methyl transferase are associated with azathioprine-induced leucopenia. Gastroenterology 2000; 118: A338.

 

68.       Fraser AG, Orchard TR, Jewell DP.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.  Gut 2002; 50: 485-489.

69.       Fraser AG, Morton D, McGovern D, Travis S, Jewell DP.  The efficacy of methotrexate for maintaining remission in inflammatory bowel disease.  Aliment Pharmacol Therap 2002; 16: 693-697.

70.       Ogra R, Lane MR, Wong P, Fraser AG. Endoscopic injection therapy for non-variceal upper gastrointestinal bleeding at Auckland Hospital. New Zealand Medical Journal 2002; 115:U255.

71.       Fraser AG. Low-dose methotrexate in ulcerative colitis: still a matter of debate – Reply. Eur J Gastro and Hepatol 2004; 16:1072.

72.       Paoluzi OA, Pica R, Iacopini F, Paoluzi P, Fraser A.G. Low-dose methotrexate in ulcerative colitis: Still a matter of debate. European Journal of Gastroenterology and Hepatology 2004;16: 1071-1072.

73.       Fraser AG, Orchard TR, Robinson EM, Jewell DP.  Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.  Aliment Pharmacol Therap 2002; 16: 1225-1232.

74.       Fraser AG, Warren BF, Chandrapala R, Jewell DP.  Microscopic colitis: a clinical and pathological review.  Scand J Gastroenterol 2002; 11: 1241-45.

75.       Fraser AG, Scragg RK, Cox B, Jackson RT.  Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction.  Int Med J 2003; 33: 267-272.

76.       Fraser AG, Williamson S, Lane MR, Hollis B.  Nurse-led dyspepsia clinic using the urea breath test for H.pylori.  NZ Med J 2003; 116: 479-83.

77.       Fraser AG.  Helicobacter pylori: a historical perspective 1983-2003.  NZ Med J; 2004; 117: 1194

78.       Fraser AG, Kandiel A, Korelitz  BI,  Brensinger C,  Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54, 1121-1125

79.     Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Abbott WG, Krissansen GW.  Polymorphisms of CARD15/NOD2 and CD14 genes in New Zealand Crohn's disease patients. Immunology and Cell Biology 2005; 83: 498-503.

 

80.       Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Abbott WGH, Krissansen GW Peroxisome proliferator-activated receptor-g gene polymorphisms and Crohn's disease. Int J Colorectal Dis 2007; 22:453-4.

81.       Leung E, Hong J, Fraser AG, et al.  Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn’s diseas in a New Zealand caucasian cohort.  Immunoly and Cell Biology 2006; 84: 233-6.

82.       Leung E, Hong J, Fraser AG, Merriman T, Krissansen G.  PPAR-gamma and Crohn’s disease.  Gastroenterology 2005; 128:351-60.  Author reply Gastroenterology 2006; 130:2249-50.

 

83.       Leung E, Hong J, Fraser AG, Merriman T, Krissansen G.  PPAR-gamma and Crohn’s disease.  Gastroenterology 2005; 128:351-60.  Author reply: Gastroenterology 2006; 130:2249-50.

84.       Leung E, Hong J, Fraser AG, Krissansen GW.  Spicing of NOD2 (CARD15) RNA transcripts.  Molecular Immunology 2007; 8:995-6.

85.       Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Krissansen GW.  Colony-stimulating factor-1 receptor gene polymorphisms.  Int J Colorect Dis 2007; 8: 995-6.

86.       Leung E. Hong J. Fraser AG. Merriman TR. Vishnu P. Krissansen GW. Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn's disease in a New Zealand Caucasian cohort. Immunology & Cell Biology 2006; 84:233-6.
 

87.       Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol 2007: 22: 1760-1766.
 

88.       Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. Polymorphisms in NFKBIA and ICAM-1 genes in New Zealand Caucasian Crohn's disease patients.  J Gastroenterol  Hepatol 2007; 22: 1666-1670.

89.       Hong J, Leung E, Fraser AG, Krissansen GW. Nucleic acid from saliva and salivary cells for noninvasive genotyping of Crohn's disease patients. Genetic Testing 2008; 12:587-9.

90.       Han DY, Fraser AG, Ferguson LR, Dryland, P. Environmental factors in the development of chronic inflammation: A case-control study on risk factors for Crohn,s disease within New Zealand. Mutation Research 2010; 690:116-122.

91.       Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW.  IL4, IL10, IL16, and TNF polymorphisms in New Zealand Caucasian Crohn's disease patients. Int Journal of Colorectal Disease 2008; 23:335-337.

92.       Triggs CM, Munday K, Hu R, Fraser AG, Gearry RB, Barclay ML, Ferguson LR. Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutation Research 2010; 690:123-138.

93.       Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR.  IL23R and IL12B SNPs and Haplotypes Strongly Associate with Crohn's Disease Risk in a New Zealand Population. Gastroenterol Res Pract 2010; 539461

94.       Fraser AG, Scragg R, Schaaf D, Metcalf PA, Grant CC. Helicobacter pylori and iron deficiency in teenage females in New Zealand. New Zealand Medical Journal 2010;123:38-45.

95.       Schultz M, Gearry R, Walmsley R, Day AS, Fraser A, Wyeth J, Barclay M, Clover G, Whiteside C. New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease. New Zealand Medical Journal 2010; 123:134-44.

96.       Nolan DJ, Tapsell LC, Han DY, Lam WJ, Morgan AR, Fraser AG, Ferguson LR. Genetic adult lactase persistence is associated with risk of Crohn's Disease in a New Zealand population. BMC Research Notes 2010: 3.

97.       Morgan, AR, Han, DY, Lam, WJ, Fraser AG, Ferguson LR. Association analysis of 3p21 with Crohn's disease in a New Zealand population. Hum Immunol 2010; 71: 602-609.

98.       Morgan AR, Han DY, Huebner C, Lam WJ, Fraser AG, Ferguson LR. PTPN2 but not PTPN22 is associated with Crohn's disease in a New Zealand population. Tissue Antigens 2010; 76: 119-125.

99.       Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Karunasinghe N.  Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 2010; 690:108-115.

100.    Wang AH, Lam WJ, Han DY, Ding Y, Hu R, Fraser  AG, Morgan A. The effect of IL-10 genetic variation and interleukin 10 serum levels of Crohn's disease susceptibility in a New Zealand population. Hum Immunol 2011, 72: 431-435.

101.    Morgan AR, Han D-Y, Lam W-J, Triggs CM, Fraser AG, Barclay M, Ferguson LR. Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology 2011; 72:1117-27.

102.    Morgan AR, Fraser AG, Ferguson LR.  Metallothionein genes: no association with Crohn's disease in a New Zealand population. J Negat Results Biomed. 2012; 28;11:8.

103.    Morgan AR, Lam WJ, Han DY, Fraser AG, Ferguson LR. Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population. Hum Immunol. 2012;73:416-20.

 

104.    Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, Karunasinghe N, Campbell B, Ferguson LR. Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand. Nutrients. 2012:9; 1247-59

105.    Atkinson NS, Fraser AG, Gala G, Gamble GD, Lane M. Colorectal cancer after colonoscopy: risk factors and survival data compared with cancer diagnosed at time of colonoscopy.  J Gastroenterology Hepatology 2012; 27: 30.
 

106.    Campbell B, Han DY, Triggs CM, Fraser AG, Ferguson LR. Brassicaceae: nutrient analysis and investigation of tolerability in people with Crohn's disease inpeople with Crohn's disease in a New Zealand study.  Functional Foods in Health and Disease 2012; 2:460-486.

 

107.    Morgan AR, Lam WJ, Han DY, Fraser AG, Ferguson LR.  DNase1: No Association with Crohn's Disease in a New Zealand Population. Gastroenterology Res Pract. 2012:826323

108.    Morgan AR, Lam WJ, Han DY, Fraser AG, Ferguson LR. Association Analysis of ULK1 with Crohn's Disease in a New Zealand Population. Gastroenterol Res Pract. 2012;715309.

109.    Fraser AG, Gamble, GD, Rose, TR, Dunn JP. Colonoscopy audit over 10 years-what can be learnt? New Zealand Medical Journal 2013; 126: 25-35.

110.    Fraser AG, Gamble GD, Rose TR. How much extra value is given to a colonoscopy audit if polyp histology is included? J Gastroenterology Hepatology 2013; 28: 23-24.

111.    Marlow G, Ellett S, Ferguson IR, Zhu S, Karunasinghe N, Jesuthasan AC, Han DY, Fraser AG, Ferguson LR.  Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients. Hum Genomics. 2013: 27;7-24.

 

112.    Fraser A. Coeliac disease – an update. Int Med Journal 2014; 44:8-8.

 

113.    Fraser AG.  Commentary: Individual vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014; 39:438-9.

 

114.    Fraser AG. Editorial: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease.  Alimentary Pharmacology & Therapeutics 2015; 41(2).

 

115.    Fraser AG. Monoclonals against TNF are a major advance in the treatment of Crohn's disease.New Zealand Medical Journal. 2014; 127:10-4.

 

116.    Krissansen GW, Yang Y, McQueen FM, Leung E, Peek D, Chan YC, Print C, Dalbeth N, Williams M, Fraser AG. Overexpression of miR-595 and miR-1246 in the Sera of Patients with Active Forms of Inflammatory Bowel Disease. Inflammatory bowel diseases 2015; 21:520-530.

 

 

 

Reviews, book chapters

 

1.          Fraser AG.  Antiulcer drugs. New Ethicals February 1992 (revised and reprinted March 1994)

 

2.          Pounder RE, Fraser AG.  Duodenal ulceration. Recent advances in Gastroenterolgy . 9th edition 1992,  pp105-118.

 

3.          Fraser AG. Gastro-oesophageal reflux and laryngeal symptoms. Aliment Pharmacol Therap 1994; 8: 265-272.

 

4.          Pounder RE, Fraser AG. Peptic ulceration. Diagnosis, medical management and complications.  In  Bockus Gastroenterology. Ed. Haubrick, Schaffner, Berk, 5th edition 1994  pp 749-790.

 

5.          Pounder RE, Fraser AG. Gastric acid secretion: measurement in health and disease. Balliere's Clinical Gastroenterology,  March 1993, Vol 7, No 1, pp 55-80.

 

6.          Richards J, Charlesworth P, Fraser A.  Therapeutic Forum - Reflux oesophagitis.  Patient Management   April 1994 (reprinted 1997).

 

7.          Fraser AG,  Rose T.  Nausea and vomiting.  Patient Management, November 1994 (reprinted 1997).

 

8.          Rose T, Fraser AG.  Dysphagia.  Patient Management,  February1995.

 

9.          Rose T, Fraser AG.  Hepatitis A to E.  Patient Management,  October1995

 

10.       Fraser AG.  Dyspepsia.  Patient Management,  December 1995 .

 

11.       Rose T, Fraser AG.  Chronic diarrhoea. - a clinical approach.  Patient Management  Dec 1996

 

12.       Fraser AG.  Editorial.  How helpful are tests for Helicobacter pylori in general practice.  New Ethicals  Feb1997, pp 9-16.

 

13.       Fraser AG.  Review.  The effect of alcohol on the pharmacokinetics of drug therapy.  Clin Pharmacokinetics 1997; 33: 79-90.

 

14.       Fraser AG.  Is there an interaction between H₂-antagonists and alcohol?  Drug Metabolism and Drug Interactions  1998; 14: 123-146.

 

15.       Fraser AG.  Microscopic colitis.  Medicine International 2003; 31(2): 82-3.

 

16.       Fraser AG.   Interpretation of liver enzyme tests: a rapid guide.  NZ Family Physician 2002; 29 (2):  117-120.

 

17.       Fraser AG.  Methotrexate:  first or second-line immunomodulator?  Eur J Gastroenterol Hepatol 2003; 15(3):225-231.

 

18.       Fraser AG.  Inflammatory bowel disease.  NZ Family Physician. 2003; 30: 425-30.

 

19.       Fraser AG.  Coeliac disease.  NZ Family Physician 2004; 31:161-64

 

20.       Fraser AG.  Fatty liver.  NZ Family Physician 2004; 31: 399-401

 

21.       Fraser AG, Barnett MPG. (2010). Animal Models of Colitis: Lessons Learned, and Their Relevance to the Clinic. In Ulcerative Colitis - Treatments.Special Populations and the Future. Intech.